AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01047085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: impedance pH measurement
Description: Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
Study NCT01047085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: impedance pH measurement
Description: Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
Study NCT04391556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firmagon
Description: 120 mg subcutaneous Injection of Firmagon after a TEP-PSMA
Study NCT01919957 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Study NCT00863057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: During each treatment period, participants will take duloxetine in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
Study NCT00863057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine placebo
Description: During each treatment period, participants will take duloxetine placebo in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
Study NCT00863057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: During each treatment period, participants will take methadone in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
Study NCT00863057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone placebo
Description: During each treatment period, participants will take methadone placebo in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
Study NCT01155063 — intervention group
Intervention type: OTHER
Intervention: Aromasin (exemestane)
Description: Aromasin (exemestane), tablets 25 mg, once a day
Study NCT04835298 — intervention group
Intervention type: OTHER
Intervention: Dyspnea
Description: questionnaires
Study NCT01569503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagus nerve stimulation (VNS)
Description: VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
Study NCT00775983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laminaria
Description: place device in cervix for dilation
Study NCT00775983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilapan-S
Description: Place in cervix for dilation.
Study NCT01843907 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Empowerment
Description: To give patients the necessary resources to take care of their own health
Study NCT01843907 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conversation with nurse
Description: To find out, if the nurse, using her ....
Study NCT04315012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: receive mobile app-based education
Description: to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
Study NCT02154113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrashape
Description: All subjects receive 3 successive Ultrashape treatments every two weeks in the anterior abdomen.
Study NCT02154113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Velashape II
Description: All subjects receive 3 successive Velashape treatments every two weeks in the anterior abdomen.
Study NCT02362854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional peri-implantitis treatment
Description: Elimination of the bacterial plaque. Establishing optimal healing conditions. Detoxification of the affected environment.
Study NCT02362854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DL application in peri-implantitis
Description: Diode laser application in the diseased implants.
Study NCT01947556 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: insulin aspart
Description: After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.
Study NCT01074021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy:~Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)
Study NCT01074021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo plus chemoradiotherapy
Description: Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)
Study NCT02291107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat (Hocoma, Zurich, Switzerland)
Description: Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
Study NCT02291107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
Study NCT04336267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) group
Description: Patients randomized to the tDCS group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity of anodal stimulation.
Study NCT04336267 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: In the sham group, the stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session.
Study NCT00708630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended information on side effects
Description: More detailed information on possible side effects of vaccine
Study NCT03413527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS Treatment
Study NCT01398592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: 50mg vildagliptin bid
Study NCT01398592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100mg sitagliptin po qd
Study NCT01604382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: General Anesthesia as described above
Study NCT01604382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neuraxial anesthesia
Description: Neuraxial anesthesia as described above
Study NCT03769181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT03769181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT01585233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKP1240
Description: Intravenous
Study NCT01585233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study NCT01239147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet rich in whole grain
Description: Ready-to-eat breakfast cereals and other cereal products, rich in whole grain
Study NCT01239147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Refined grain
Description: Ready-to-eat breakfast cereals and other cereal products, low in whole grain
Study NCT04050800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon 11 Butanol
Description: Two sequential administrations of a PET tracer
Study NCT02431403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESHAP-Imatinib
Description: After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
Study NCT04534192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JADE Balloon
Description: Suitable TASC C and D lesions will be treated with non-compliant high pressure JADE balloon.
Study NCT00787566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal granisetron
Description: 0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen
Study NCT04485286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.
Study NCT04726917 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pulmonary rehabilitation
Description: Patients qualified for rehabilitation were assessed for stress levels as well as symptoms of anxiety and depression before rehabilitation began
Study NCT04496089 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-girentuximab
Description: A single dose of 37 MBq (±10%) is administered. The dose per dose is equivalent to girentuximab 10 mg (±10%).
Study NCT03734679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurVeil Drug Coated Balloon
Description: Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
Study NCT06064981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message nudges
Description: Fourteen text message nudges, tailored to address specific barriers and concerns regarding naloxone acquisition and carrying. These barriers were identified using qualitative interviews conducted by the authors in prior studies. Examples included: optimism bias (e.g., beliefs that participants were unlikely to encounter someone who had overdosed in their daily lives), and identity bias (e.g., beliefs that participants were not the type of people who could save a life).
Study NCT06064981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment contract
Description: In addition to the training, participants in the third arm were asked to sign commitment contracts, which had language in which they committed to carrying/acquiring naloxone.
Study NCT04057755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A
Study NCT04057755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A
Study NCT04057755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl
Study NCT04057755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study NCT02531828 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of dressings for surgical correction.
Description: Dressing for surgical correction
Study NCT02531828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POLYSHAFT®
Study NCT06156969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training
Description: Training will be performed using the LokomatPro. The Lokomat consists of a driven (motorized) gait orthosis (DGO) and an advanced body weight support system, combined with a treadmill. It uses computer-controlled motors which are integrated in the gait orthosis at each hip and knee joint. The exoskeleton is secured to a person's lower limbs using straps.~Training protocol: Each training session will include 30 minutes of gait training. Training will take over a period of about 6-7 weeks. Sessions will last approximately 60 minutes.
Study NCT04467333 — intervention group
Intervention type: OTHER
Intervention: All lung cancer patients.
Description: There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.
Study NCT00718965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530
Description: one tablet in the evening with dinner
Study NCT00718965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet in the evening with dinner
Study NCT01484990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-Carbidopa
Description: Intestinal Gel
Study NCT03676374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 2mg taken once a day as add-on to PPI (2x/d)
Study NCT03676374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet taken once a day as add-on to PPI (2x/d)
Study NCT00936975 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Sodium Fluoride
Description: Undergo fluorine F 18 sodium fluoride PET scan
Study NCT03652961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept for reconstitution and dilution prior to intravenous (IV) administration. Each single-use vial of Abatacept for injection provides 250-mg Abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration.
Study NCT03652961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.
Study NCT04256993 — intervention group
Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Follow the physician's prescription in routine clinical practice. This study does not involve prescription of the drugs.
Study NCT04256993 — intervention group
Intervention type: DRUG
Intervention: Other standard care
Description: Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.
Study NCT03706677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon (Arctic Front Advance Cryoballoon)
Description: Ablation using a Cryoballoon catheter (Arctic Front Advance Cryoballoon Cardiac Ablation Catheter)
Study NCT03706677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Catheter (ThermoCool Smarttouch)
Description: Ablation using a Radiofrequency ablation catheter (ThermoCool Smarttouch catheter)
Study NCT01557270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
Study NCT01557270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: ropivacaine + saline placebo, single shot perineural application
Study NCT00990561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate ointment twice daily + LacHydrin lotion twice daily
Description: Topical corticosteroid
Study NCT00990561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate ointment once daily + LacHydrin lotion twice daily
Description: Topical corticosteroid
Study NCT00395083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD Self-management Education
Description: The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
Study NCT04204486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Functional strength training, 1 hour, 3 times a week.
Study NCT04204486 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Functional strength training, 1 hour, 3 times a week.
Study NCT04305223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Dry Needling is a treatment technique whereby a sterile, single-use, fine filament needle is inserted into the muscle to assist with decreasing pain and improving function through the release of myofascial trigger points (knots in the muscle).
Study NCT04305223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry Needling is a treatment technique whereby a sterile, single-use, fine filament needle is inserted into the muscle to assist with decreasing pain and improving function through the release of myofascial trigger points (knots in the muscle).
Study NCT04305223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity stretching program
Description: A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter
Study NCT02600806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Patients are given oral azithromycin when procalcitonin levels are \< 0.5 ng/ml
Study NCT02600806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levofloxacin
Description: Patients are given oral levofloxacin when procalcitonin levels are >= 0.5 ng/ml.
Study NCT06024863 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Screening stress test on a bicycle ergometer (usual practise)
Study NCT03111147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0 degrees humeral component version
Description: RTSA with humeral component positioned in 0 degrees of version
Study NCT03111147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 degrees humeral component retroversion
Description: RTSA with humeral component positioned in 30 degrees of retroversion
Study NCT00345683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)
Description: Booster dose by intramuscular injection
Study NCT00345683 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PedvaxHIB
Description: Booster dose by intramuscular injection
Study NCT00345683 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: Booster dose by intramuscular injection
Study NCT00345683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: Booster dose by intramuscular injection
Study NCT00345683 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: Single dose by subcutaneous injection